Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress

Author(s): Javed Ahmad*, Ameeduzzafar, Mohammad Z. Ahmad, Habban Akhter

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 11 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Cancer is highly heterogeneous in nature and characterized by abnormal, uncontrolled cells’ growth. It is responsible for the second leading cause of death in the world. Nanotechnology is explored profoundly for sitespecific delivery of cancer chemotherapeutics as well as overcome multidrug-resistance (MDR) challenges in cancer. The progress in the design of various smart biocompatible materials (such as polymers, lipids and inorganic materials) has now revolutionized the area of cancer research for the rational design of nanomedicine by surface engineering with targeting ligands. The small tunable size and surface properties of nanomedicines provide the opportunity of multiple payloads and multivalent-ligand targeting to achieve drug efficacy even in MDR cancer. Furthermore, efforts are being carried out for the development of novel nano-pharmaceutical design, focusing on the delivery of therapeutic and diagnostic agents simultaneously which is called theranostics to assess the progress of therapy in cancer. This review aimed to discuss the physicochemical manipulation of cancer nanomedicine for rational design and recent progress in the area of surface engineering of nanomedicines to improve the efficacy of cancer chemotherapeutics in MDR cancer as well. Moreover, the problem of toxicity of the advanced functional materials that are used in nanomedicines and are exploited to achieve drug targeting in cancer is also addressed.

Keywords: Cancer, multi-drug resistance (MDR), nanomedicine, surface-engineering, targeting, theranostics, toxicity apprehension.

[1]
Ahmad J, Akhter S, Greig NH, Kamal MA, Midoux P, Pichon C. Engineered nanoparticles against MDR in cancer: The state of the art and its prospective. Curr Pharm Des 2016; 22(28): 4360-73.
[http://dx.doi.org/10.2174/1381612822666160617112111] [PMID: 27319945]
[2]
Akhter S, Amin S, Ahmad J, et al. Resistance to targeted anti-cancer therapeutics. Springer International Publishing Switzerland 2015; Vol. 4: 245-72.
[http://dx.doi.org/10.1007/978-3-319-09801-2_10]
[3]
World Health Organization. Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer
[4]
Ahmad J, Mir SR, Kohli K, et al. Quality by design approach for self-nanoemulsifying system for paclitaxel. Sci Adv Mater 2014; 6: 1778-91.
[http://dx.doi.org/10.1166/sam.2014.1884]
[5]
Kuncic Z. Cancer nanomedicine: challenges and opportunities. Med J Aust 2015; 203(5): 204-5, 1.
[http://dx.doi.org/10.5694/mja15.00681] [PMID: 26852043]
[6]
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2017; 17(1): 20-37.
[http://dx.doi.org/10.1038/nrc.2016.108] [PMID: 27834398]
[7]
Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science 2006; 311(5761): 622-7.
[http://dx.doi.org/10.1126/science.1114397] [PMID: 16456071]
[8]
Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009; 38(6): 1759-82.
[http://dx.doi.org/10.1039/b806051g] [PMID: 19587967]
[9]
Ahmad J, Amin S, Rahman M, et al. Solid matrix based lipidic nano-approach in oral cancer chemotherapy: Application and pharmacokinetics. Curr Drug Metab 2015; 16(8): 633-44.
[http://dx.doi.org/10.2174/1389200216666150812122128] [PMID: 26264206]
[10]
Ahmad J, Mir SR, Kohli K, et al. Solid-nanoemulsion preconcentrate for oral delivery of paclitaxel: formulation design, biodistribution, and γ scintigraphy imaging. BioMed Res Int 2014; 2014984756
[http://dx.doi.org/10.1155/2014/984756] [PMID: 25114933]
[11]
Navya PN, Daima HK. Rational engineering of physicochemical properties of nanomaterials for biomedical applications with nanotoxicological perspectives. Nano Converg 2016; 3(1): 1-14.
[http://dx.doi.org/10.1186/s40580-016-0064-z] [PMID: 28191411]
[12]
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 2015; 200: 138-57.
[http://dx.doi.org/10.1016/j.jconrel.2014.12.030] [PMID: 25545217]
[13]
Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19(3): 311-30.
[http://dx.doi.org/10.1096/fj.04-2747rev] [PMID: 15746175]
[14]
Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58(14): 1456-9.
[http://dx.doi.org/10.1016/j.addr.2006.09.011] [PMID: 17070960]
[15]
Salata O. Applications of nanoparticles in biology and medicine. J Nanobiotechnology 2004; 2(1): 3.
[http://dx.doi.org/10.1186/1477-3155-2-3] [PMID: 15119954]
[16]
Thanh NTK, Green LAW. Functionalisation of nanoparticles for biomedical applications. Nano Today 2010; 5(3): 213-30.
[http://dx.doi.org/10.1016/j.nantod.2010.05.003]
[17]
Sanvicens N, Marco MP. Multifunctional nanoparticles--properties and prospects for their use in human medicine. Trends Biotechnol 2008; 26(8): 425-33.
[http://dx.doi.org/10.1016/j.tibtech.2008.04.005] [PMID: 18514941]
[18]
Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009; 8(7): 543-57.
[http://dx.doi.org/10.1038/nmat2442] [PMID: 19525947]
[19]
Tang L, Yang X, Yin Q, et al. Investigating the optimal size of anticancer nanomedicine. Proc Natl Acad Sci USA 2014; 111(43): 15344-9.
[http://dx.doi.org/10.1073/pnas.1411499111] [PMID: 25316794]
[20]
Whitesides GM. The ‘right’ size in nanobiotechnology. Nat Biotechnol 2003; 21(10): 1161-5.
[http://dx.doi.org/10.1038/nbt872] [PMID: 14520400]
[21]
Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) 2008; 3(5): 703-17.
[http://dx.doi.org/10.2217/17435889.3.5.703] [PMID: 18817471]
[22]
Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008; 3(3): 145-50.
[http://dx.doi.org/10.1038/nnano.2008.30] [PMID: 18654486]
[23]
Gao L, Zhuang J, Nie L, et al. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat Nanotechnol 2007; 2(9): 577-83.
[http://dx.doi.org/10.1038/nnano.2007.260] [PMID: 18654371]
[24]
Bansal V, Li V, O’Mullane AP, Bhargava SK. Shape dependent electrocatalytic behaviour of silver nanoparticles. CrystEngComm 2010; 12(12): 4280-6.
[http://dx.doi.org/10.1039/c0ce00215a]
[25]
Burda C, Chen X, Narayanan R, El-Sayed MA. Chemistry and properties of nanocrystals of different shapes. Chem Rev 2005; 105(4): 1025-102.
[http://dx.doi.org/10.1021/cr030063a] [PMID: 15826010]
[26]
Narayanan R, El-Sayed MA. Shape-dependent catalytic activity of platinum nanoparticles in colloidal solution. Nano Lett 2004; 4(7): 1343-8.
[http://dx.doi.org/10.1021/nl0495256]
[27]
Mahmoudi M, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, Laurent S. Protein-nanoparticle interactions: opportunities and challenges. Chem Rev 2011; 111(9): 5610-37.
[http://dx.doi.org/10.1021/cr100440g] [PMID: 21688848]
[28]
Mahmoudi M, Azadmanesh K, Shokrgozar MA, Journeay WS, Laurent S. Effect of nanoparticles on the cell life cycle. Chem Rev 2011; 111(5): 3407-32.
[http://dx.doi.org/10.1021/cr1003166] [PMID: 21401073]
[29]
Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol 2007; 73(6): 1712-20.
[http://dx.doi.org/10.1128/AEM.02218-06] [PMID: 17261510]
[30]
Kallay N, Zalac S. Stability of nanodispersions: a model for kinetics of aggregation of nanoparticles. J Colloid Interface Sci 2002; 253(1): 70-6.
[http://dx.doi.org/10.1006/jcis.2002.8476] [PMID: 16290832]
[31]
Richards R, Bönnemann H. Nanofabrication towards biomedical applications. New York: Wiley-VCH Verlag GmbH & Co. KGaA 2005; 81: 1-32.
[32]
Thanh NTK, Rosenzweig Z. Development of an aggregation-based immunoassay for anti-protein A using gold nanoparticles. Anal Chem 2002; 74(7): 1624-8.
[http://dx.doi.org/10.1021/ac011127p] [PMID: 12033254]
[33]
Sato K, Hosokawa K, Maeda M. Rapid aggregation of gold nanoparticles induced by non-cross-linking DNA hybridization. J Am Chem Soc 2003; 125(27): 8102-3.
[http://dx.doi.org/10.1021/ja034876s] [PMID: 12837070]
[34]
Lok CN, Ho CM, Chen R, et al. Silver nanoparticles: partial oxidation and antibacterial activities. J Biol Inorg Chem 2007; 12(4): 527-34.
[http://dx.doi.org/10.1007/s00775-007-0208-z] [PMID: 17353996]
[35]
Soenen SJ, Parak WJ, Rejman J, Manshian B. (Intra)cellular stability of inorganic nanoparticles: effects on cytotoxicity, particle functionality, and biomedical applications. Chem Rev 2015; 115(5): 2109-35.
[http://dx.doi.org/10.1021/cr400714j] [PMID: 25757742]
[36]
Sée V, Free P, Cesbron Y, et al. Cathepsin L digestion of nanobioconjugates upon endocytosis. ACS Nano 2009; 3(9): 2461-8.
[http://dx.doi.org/10.1021/nn9006994] [PMID: 19728690]
[37]
Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011; 7(10): 1322-37.
[http://dx.doi.org/10.1002/smll.201100001] [PMID: 21520409]
[38]
Cedervall T, Lynch I, Lindman S, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 2007; 104(7): 2050-5.
[http://dx.doi.org/10.1073/pnas.0608582104] [PMID: 17267609]
[39]
Tenzer S, Docter D, Kuharev J, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol 2013; 8(10): 772-81.
[http://dx.doi.org/10.1038/nnano.2013.181] [PMID: 24056901]
[40]
Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl 2009; 48(5): 872-97.
[http://dx.doi.org/10.1002/anie.200802585] [PMID: 19142939]
[41]
Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012; 7(12): 779-86.
[http://dx.doi.org/10.1038/nnano.2012.207] [PMID: 23212421]
[42]
Daima HK, Selvakannan PR, Kandjani AE, Shukla R, Bhargava SK, Bansal V. Synergistic influence of polyoxometalate surface corona towards enhancing the antibacterial performance of tyrosine-capped Ag nanoparticles. Nanoscale 2014; 6(2): 758-65.
[http://dx.doi.org/10.1039/C3NR03806H] [PMID: 24165753]
[43]
Daima HK, Selvakannan PR, Shukla R, Bhargava SK, Bansal V. Fine-tuning the antimicrobial profile of biocompatible gold nanoparticles by sequential surface functionalization using polyoxometalates and lysine. PLoS One 2013; 8(10)e79676
[http://dx.doi.org/10.1371/journal.pone.0079676] [PMID: 24147146]
[44]
Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release 2010; 145(3): 182-95.
[http://dx.doi.org/10.1016/j.jconrel.2010.01.036] [PMID: 20226220]
[45]
Chung TH, Wu SH, Yao M, et al. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 2007; 28(19): 2959-66.
[http://dx.doi.org/10.1016/j.biomaterials.2007.03.006] [PMID: 17397919]
[46]
Arvizo RR, Miranda OR, Thompson MA, et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett 2010; 10(7): 2543-8.
[http://dx.doi.org/10.1021/nl101140t] [PMID: 20533851]
[47]
Wiesner MR, Lowry GV, Alvarez P, Dionysiou D, Biswas P. Assessing the risks of manufactured nanomaterials. Environ Sci Technol 2006; 40(14): 4336-45.
[http://dx.doi.org/10.1021/es062726m] [PMID: 16903268]
[48]
Ozay O, Akcali A, Otkun MT, Silan C, Aktas N, Sahiner N. P(4-VP) based nanoparticles and composites with dual action as antimicrobial materials. Colloids Surf B Biointerfaces 2010; 79(2): 460-6.
[http://dx.doi.org/10.1016/j.colsurfb.2010.05.013] [PMID: 20510589]
[49]
Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009; 6(3): 659-68.
[http://dx.doi.org/10.1021/mp900015y] [PMID: 19267452]
[50]
Carlson C, Hussain SM, Schrand AM, et al. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B 2008; 112(43): 13608-19.
[http://dx.doi.org/10.1021/jp712087m] [PMID: 18831567]
[51]
Bose RJ, Paulmurugan R, Moon J, Lee SH, Park H. Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics. Drug Discov Today 2018; 23(4): 891-9.
[http://dx.doi.org/10.1016/j.drudis.2018.02.001] [PMID: 29426004]
[52]
Andresen TL, Jensen SS, Jørgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 2005; 44(1): 68-97.
[http://dx.doi.org/10.1016/j.plipres.2004.12.001] [PMID: 15748655]
[53]
Rizwanullah M, Amin S, Ahmad J. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. J Drug Target 2017; 25(1): 58-74.
[http://dx.doi.org/10.1080/1061186X.2016.1191080] [PMID: 27186665]
[54]
Rizwanullah M, Ahmad J, Amin S. Nanostructured lipid carriers: a novel platform for chemotherapeutics. Curr Drug Deliv 2016; 13(1): 4-26.
[http://dx.doi.org/10.2174/1567201812666150817124133] [PMID: 26279117]
[55]
Ahmad J, Kohli K, Mir SR, et al. Lipid based nanocarriers for oral delivery of cancer chemotherapeutics: An insight in the intestinal lymphatic transport. Drug Deliv Lett 2013; 3(1): 38-46.
[http://dx.doi.org/10.2174/2210304x11303010006]
[56]
Shim G, Yu YH, Lee S, Kim J, Oh YK. Surface-modified liposomes for syndecan 2–targeted delivery of edelfosine. Asian J Pharm Sci 2016; 11(5): 596-602.
[http://dx.doi.org/10.1016/j.ajps.2016.05.003]
[57]
Jain A, Kesharwani P, Garg NK, et al. Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin. Colloids Surf B Biointerfaces 2015; 134: 47-58.
[http://dx.doi.org/10.1016/j.colsurfb.2015.06.027] [PMID: 26142628]
[58]
Negi LM, Talegaonkar S, Jaggi M, et al. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation. Colloids Surf B Biointerfaces 2014; 123: 600-9.
[http://dx.doi.org/10.1016/j.colsurfb.2014.09.062] [PMID: 25454761]
[59]
Marengo A, Forciniti S, Dando I, et al. Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes. Biochim Biophys Acta, Gen Subj 2019; 1863(1): 61-72.
[http://dx.doi.org/10.1016/j.bbagen.2018.09.018] [PMID: 30267751]
[60]
Zhang L, Zhang L. Lipid-polymer hybrid nanoparticles: synithesis, characterization and applications. Nano Life 2010; 1: 163-73.
[http://dx.doi.org/10.1142/S179398441000016X]
[61]
Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307(1): 93-102.
[http://dx.doi.org/10.1016/j.ijpharm.2005.10.010] [PMID: 16303268]
[62]
Salvador-Morales C, Zhang L, Langer R, Farokhzad OC. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009; 30(12): 2231-40.
[http://dx.doi.org/10.1016/ j.biomaterials.2009.01.005] [PMID: 19167749]
[63]
Chambon P, Chen L, Furzeland S, et al. Poly(N-isopropylacrylamide) branched polymer nanoparticles. Polym Chem 2011; 2: 941-9.
[http://dx.doi.org/10.1039/ c0py00369g]
[64]
Zhang YT, Hou JW, Qian CY, Song L, Guo SR. Taxol-loaded nanoparticles with methoxy poly(ethylene glycol)-b-poly(epsilon-caprolactone) as a novel additive in the outer aqueous phase. J Appl Polym Sci 2011; 121: 2386-93.
[http://dx.doi.org/10.1002/app.33518]
[65]
Liu Y, Pan J, Feng SS. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm 2010; 395(1-2): 243-50.
[http://dx.doi.org/10.1016/j.ijpharm.2010.05.008] [PMID: 20472049]
[66]
Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J Control Release 2002; 80(1-3): 129-44.
[http://dx.doi.org/10.1016/S0168-3659(02)00025-1] [PMID: 11943393]
[67]
Akhtar N, Ahad A, Khar RK, et al. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Pat 2011; 21(4): 561-76.
[http://dx.doi.org/10.1517/13543776.2011.561784] [PMID: 21413912]
[68]
Shieh MJ, Hsu CY, Huang LY, Chen HY, Huang FH, Lai PS. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release 2011; 152(3): 418-25.
[http://dx.doi.org/10.1016/j.jconrel.2011.03.017] [PMID: 21435362]
[69]
Wang G, Yu B, Wu Y, Huang B, Yuan Y, Liu CS. Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel. Int J Pharm 2013; 446(1-2): 24-33.
[http://dx.doi.org/10.1016/j.ijpharm.2013.02.004] [PMID: 23402977]
[70]
Ahmed A, Wang H, Yu H, et al. Surface engineered cyclodextrin embedded polymeric nanoparticles through host–guest interaction used for drug delivery. Chem Eng Sci 2015; 125: 121-8.
[http://dx.doi.org/10.1016/j.ces.2014.07.045]
[71]
Yu H, Chen J, Liu S, et al. Enzyme sensitive, surface engineered nanoparticles for enhanced delivery of camptothecin. J Control Release 2015; 216: 111-20.
[http://dx.doi.org/10.1016/j.jconrel.2015.08.021] [PMID: 26282096]
[72]
Jiang X, Xin H, Gu J, et al. Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials 2013; 34(6): 1739-46.
[http://dx.doi.org/10.1016/j.biomaterials.2012.11.016] [PMID: 23211449]
[73]
Jain A, Jain A, Garg NK, et al. Surface engineered polymeric nanocarriers mediate the delivery of transferrin-methotrexate conjugates for an improved understanding of brain cancer. Acta Biomater 2015; 24: 140-51.
[http://dx.doi.org/10.1016/j.actbio.2015.06.027] [PMID: 26116986]
[74]
Domínguez-Ríos R, Sánchez-Ramírez DR, Ruiz-Saray K, et al. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloids Surf B Biointerfaces 2019; 178: 199-207.
[http://dx.doi.org/10.1016/j.colsurfb.2019.03.011] [PMID: 30856589]
[75]
Ahmad MZ, Abdel-Wahab BA, Alam A, et al. Toxicity of inorganic nanoparticles used in targeted drug delivery and other biomedical application: an updated account on concern of biomedical nanotoxicology. J Nanosci Nanotechnol 2016; 16(8): 7873-97.
[http://dx.doi.org/10.1166/jnn.2016.13032]
[76]
Rahman M, Akhter S, Ahmad MZ, et al. Emerging advances in cancer nanotheranostics with graphene nanocomposites: opportunities and challenges. Nanomedicine (Lond) 2015; 10(15): 2405-22.
[http://dx.doi.org/10.2217/nnm.15.68] [PMID: 26252175]
[77]
Rahman M, Ahmad MZ, Ahmad J, et al. Role of graphene nano-composites in cancer therapy: Theranostic applications, metabolic fate and toxicity issues. Curr Drug Metab 2015; 16(5): 397-409.
[http://dx.doi.org/10.2174/1389200215666141125120633] [PMID: 25429670]
[78]
Akhter S, Ramazani F, Ahmad MZ, et al. Theranostic metallic nanomedicine in oncology: New insights and concerns. Front Anti-Cancer Drug Discov 2014; 3: 262-91.
[http://dx.doi.org/10.2174/9781608058846114030010]
[79]
Heo DN, Yang DH, Moon HJ, et al. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials 2012; 33(3): 856-66.
[http://dx.doi.org/10.1016/j.biomaterials.2011.09.064] [PMID: 22036101]
[80]
Mehra NK, Jain NK. Cancer targeting propensity of folate conjugated surface engineered multi-walled carbon nanotubes. Colloids Surf B Biointerfaces 2015; 132: 17-26.
[http://dx.doi.org/10.1016/j.colsurfb.2015.04.056] [PMID: 26001798]
[81]
Hoang Thi TT, Nguyen Tran DH, Bach LG, et al. Functional magnetic core-shell system-based iron oxide nanoparticle coated with biocompatible copolymer for anticancer drug delivery. Pharmaceutics 2019; 11(3): 120.
[http://dx.doi.org/10.3390/pharmaceutics11030120] [PMID: 30875948]
[82]
Ahmad J, Akhter S, Rizwanullah M, et al. Nanotechnology-based inhalation treatments for lung cancer: state of the art. Nanotechnol Sci Appl 2015; 8: 55-66.
[PMID: 26640374]
[83]
Holl MM. Nanotoxicology: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009; 1(4): 353-9.
[http://dx.doi.org/10.1002/wnan.27] [PMID: 20049802]
[84]
Krug HF, Wick P. Nanotoxicology: an interdisciplinary challenge. Angew Chem Int Ed Engl 2011; 50(6): 1260-78.
[http://dx.doi.org/10.1002/anie.201001037] [PMID: 21290492]
[85]
Cho EC, Zhang Q, Xia Y. The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat Nanotechnol 2011; 6(6): 385-91.
[http://dx.doi.org/10.1038/nnano.2011.58] [PMID: 21516092]
[86]
Rushton EK, Jiang J, Leonard SS, et al. Concept of assessing nanoparticle hazards considering nanoparticle dosemetric and chemical/biological response metrics. J Toxicol Environ Health A 2010; 73(5): 445-61.
[http://dx.doi.org/10.1080/15287390903489422] [PMID: 20155585]
[87]
DeLoid G, Cohen JM, Darrah T, et al. Estimating the effective density of engineered nanomaterials for in vitro dosimetry. Nat Commun 2014; 5: 3514.
[http://dx.doi.org/10.1038/ncomms4514] [PMID: 24675174]
[88]
Zhao J, Castranova V. Toxicology of nanomaterials used in nanomedicine. J Toxicol Environ Health B Crit Rev 2011; 14(8): 593-632.
[http://dx.doi.org/10.1080/10937404.2011.615113] [PMID: 22008094]
[89]
Alkilany AM, Mahmoud NN, Hashemi F, Hajipour MJ, Farvadi F, Mahmoudi M. Misinterpretation in nanotoxicology: a personal perspective. Chem Res Toxicol 2016; 29(6): 943-8.
[http://dx.doi.org/10.1021/acs.chemrestox.6b00108] [PMID: 27249426]
[90]
Pulakkat S, Balaji SA, Rangarajan A, Raichur AM. Surface Engineered Protein nanoparticles with hyaluronic acid based multilayers for targeted delivery of anticancer agents. ACS Appl Mater Interfaces 2016; 8(36): 23437-49.
[http://dx.doi.org/10.1021/acsami.6b04179] [PMID: 27560126]
[91]
Jain K, Jain NK. Surface engineered dendrimers as antiangiogenic agent and carrier for anticancer drug: dual attack on cancer. J Nanosci Nanotechnol 2014; 14(7): 5075-87.
[http://dx.doi.org/10.1166/jnn.2014.8677] [PMID: 24757983]


promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 11
Year: 2020
Published on: 23 April, 2020
Page: [1181 - 1190]
Pages: 10
DOI: 10.2174/1381612826666200214110645

Article Metrics

PDF: 16
HTML: 2